(Q37251705)

19 August 2017

1 reference

title

Remission of proteinuria in primary glomerulonephritis: we know the goal but do we know the price? (English)

1 reference

19 August 2017

1 reference

2

Daniel Cattran

1 reference

19 August 2017

David Philibert

1

1 reference

19 August 2017

publication date

26 August 2008

1 reference

19 August 2017

number of pages

10

1 reference

Nature Clinical Practice Nephrology

inferred from page(s)

published in

1 reference

19 August 2017

volume

4

1 reference

19 August 2017

issue

10

1 reference

19 August 2017

page(s)

550-559

1 reference

Bronchospasm and cough as adverse reactions to the ACE inhibitors captopril, enalapril and lisinopril. A controlled retrospective cohort study

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

Controlled Trial of Methylprednisolone and Chlorambucil in Idiopathic Membranous Nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Idiopathic membranous nephropathy: definition and relevance of a partial remission

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Prognosis after a complete remission in adult patients with idiopathic membranous nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Renal pathology in idiopathic membranous nephropathy: a new perspective

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Long-term prognosis of idiopathic membranous glomerulonephritis. Study of 116 untreated patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Prediction in idiopathic membranous nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

A Randomized, Controlled Trial of Steroids and Cyclophosphamide in Adults with Nephrotic Syndrome Caused by Idiopathic Membranous Nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Cyclophosphamide in lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Efficacy of a second course of immunosuppressive therapy in patients with membranous nephropathy and persistent or relapsing disease activity

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Impact of cyclophosphamide on long-term reduction in sperm count in men treated with combination chemotherapy for Ewing and soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

The relationship of gonadal activity and chemotherapy-induced gonadal damage

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Immunosuppressive drugs and cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Cancer incidence after immunosuppressive treatment following kidney transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Stable kidney function in the second decade after kidney transplantation while on cyclosporine-based immunosuppression.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Diabetes mellitus after kidney transplantation in the United States

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Does cyclosporine achieve a real advantage for treatment of idiopathic nephrotic syndrome in children? A long-term efficacy and safety study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Rituximab in idiopathic membranous nephropathy: a one-year prospective study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Rituximab treatment of idiopathic membranous nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Rituximab for Idiopathic Membranous Nephropathy: Who Can Benefit?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Focal and segmental glomerulosclerosis: definition and relevance of a partial remission

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Long-term outcome in children and adults with classic focal segmental glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome : workshop recommendations

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Sirolimus Therapy of Focal Segmental Glomerulosclerosis Is Associated With Nephrotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Epidemiologic data of primary glomerular diseases in western France

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analyses

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Deterioration of GFR in IgA nephropathy as measured by 51Cr-EDTA clearance

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Remission of proteinuria improves prognosis in IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Predicting progression in IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

ACE inhibitor-induced angioedema. Incidence, prevention and management

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Major congenital malformations after first-trimester exposure to ACE inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Long-term results of tonsillectomy as a treatment for IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Relationship between tonsils and IgA nephropathy as well as indications of tonsillectomy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Evaluation of posttonsillectomy hemorrhage and risk factors

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Corticosteroids in IgA nephropathy: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Prednisolone and azathioprine in IgA nephropathy - a ten-year follow-up study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0915

7 January 2021

Identifiers

DOI

10.1038/NCPNEPH0915

1 reference

19 August 2017

1 reference